Margaret Tempero, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Phone415-353-7528
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of NebraskaM.D.1977School of Medicine
    Collapse Awards and Honors
    UCSF2012  - PresRombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science
    UCSF2000  - 2012Doris and Don Fisher Distinguished Professor in Clinical Research
    Journal Nat'l Comprehensive Cancer Network2014  - PresEditor-In-Chief

    Collapse Overview 
    Collapse Overview
    Dr. Tempero is Director, UCSF Pancreas Center and Leader, Pancreas Cancer Program. Her research career has focused on pancreatic ductal adenocarcinoma especially in the area of investigational therapeutics. She was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. Her group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials. Currently her group is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation.

    Dr. Tempero directed the first GI SPORE devoted to pancreatic cancer when she was on the faculty of the University of Nebraska and subsequently led the NCI funded U54 Molecular Target Assessment Team at UCSF. She also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. She has served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. She also serves on the Pancreatic Cancer Task Force for the NCI intergroup and recently co-organized the State of the Science meeting on pancreatic cancer at the NCI.

    Dr. Tempero also has extensive experience in scientific review and administration, training and oversight. She co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for 3 years and spent 9 years of service teaching this course and similar courses in Europe and Australia. She was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (2-year term) of the NCI Board of Scientific Counselors Subcommittee A. She is on the External Advisory Boards of the Pancreas SPORE at MDACC and the GI SPOREs at the University of Arizona and Northwestern. She is, or has been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. She has held many appointments at AACR and ASCO and has served as a member of the ASCO Board of Directors and as ASCO President in 2004. She recently served as a member of the Oncology Drug Advisory Committee for the FDA. She served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, Chief Emeritus of the Division of Medical Oncology at UCSF (2000 – 2007) and Deputy Director and Director of Research Programs at the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) from 2000 to 2012.

    Collapse Research 
    Collapse Research Activities and Funding
    Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
    NIH R21CA184429Sep 15, 2014 - Aug 31, 2018
    Role: Principal Investigator
    Mechanism-Based Evaluations of ErbB-Targeted Agents
    NIH U54CA090788Sep 26, 2001 - Dec 31, 2008
    Role: Principal Investigator
    Cancer Center Support Grant
    NIH P30CA082103Aug 5, 1999 - May 31, 2023
    Role: Co-Investigator
    SPORE IN GASTOINTESTINAL CANCER
    NIH P50CA072712Sep 1, 1997 - Jan 31, 2005
    Role: Co-Principal Investigator
    DEFINING TOXICITY AND BENEFIT FOR RADIOIMMUNOTHERAPY
    NIH U01CA058272Sep 30, 1993 - Sep 29, 2000
    Role: Principal Investigator
    Fred & Pamela Buffett Cancer Center Support Grant
    NIH P30CA036727Jul 1, 1984 - Jul 31, 2021
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Informed Consent: Is It Really? J Natl Compr Canc Netw. 2021 Jun 30; 19(6):665. Tempero M. PMID: 34214973.
      View in: PubMed   Mentions:    Fields:    
    2. Open Notes Are Here: Are We Ready? J Natl Compr Canc Netw. 2021 May 01; 19(5):477. Tempero M. PMID: 34030126.
      View in: PubMed   Mentions:    Fields:    
    3. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Apr 03. Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC. PMID: 33813673.
      View in: PubMed   Mentions:    Fields:    
    4. Being Closer to Normal. J Natl Compr Canc Netw. 2021 Apr 01; 19(4):363. Tempero M. PMID: 33845458.
      View in: PubMed   Mentions:    Fields:    
    5. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Apr 01; 19(4):439-457. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. PMID: 33845462.
      View in: PubMed   Mentions:    Fields:    
    6. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 Mar 16. Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Väyrynen SA, Clancy TE, Rubinson DA, Link J, Keith D, Horton W, Tempero MA, Vonderheide RH, Jaffee EM, Sheppard B, Goecks J, Sears RC, Park BS, Mori M, Nowak JA, Wolpin BM, Coussens LM. PMID: 33727309.
      View in: PubMed   Mentions: 3     Fields:    
    7. It's All About Trust! J Natl Compr Canc Netw. 2021 Mar 02; 19(3):239. Tempero M. PMID: 33668022.
      View in: PubMed   Mentions:    Fields:    
    8. Learning From Our Mistakes. J Natl Compr Canc Netw. 2021 Feb 02; 19(2):121. Tempero M. PMID: 33545686.
      View in: PubMed   Mentions:    Fields:    
    9. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 05; 32(5):600-608. Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G, James D, Macarulla T. PMID: 33539945.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    10. New Year's Resolutions - A Different Perspective. J Natl Compr Canc Netw. 2021 01 06; 19(1):1. Tempero M. PMID: 33406497.
      View in: PubMed   Mentions:    Fields:    
    11. Lasting Effects of COVID-19: Reimbursement Reform? J Natl Compr Canc Netw. 2020 11 02; 18(11):1435. Tempero M. PMID: 33152702.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    12. Flirting With Disaster: COVID-19 and Cancer. J Natl Compr Canc Netw. 2020 10 01; 18(10):1291. Tempero M. PMID: 33022645.
      View in: PubMed   Mentions:    Fields:    
    13. COVID-19 and Cancer: Unintended Consequences. J Natl Compr Canc Netw. 2020 09; 18(9):1147. Tempero M. PMID: 32886904.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    14. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020 09 01; 130(9):4704-4709. Jiang H, Torphy RJ, Steiger K, Hongo H, Ritchie AJ, Kriegsmann M, Horst D, Umetsu SE, Joseph NM, McGregor K, Pishvaian MJ, Blais EM, Lu B, Li M, Hollingsworth M, Stashko C, Volmar K, Yeh JJ, Weaver VM, Wang ZJ, Tempero MA, Weichert W, Collisson EA. PMID: 32749238.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    15. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2020 09 20; 38(27):3185-3194. Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ, HALO 109-301 Investigators . PMID: 32706635.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    16. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol Ther. 2020 11 04; 28(11):2367-2378. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. PMID: 32730744.
      View in: PubMed   Mentions: 3     Fields:    
    17. Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma. AJR Am J Roentgenol. 2020 09; 215(3):610-616. Wang ZJ, Zhang TT, An C, Ko AH, Tempero M, Collisson E, Yeh BM. PMID: 32755156.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    18. I Can't Breathe! J Natl Compr Canc Netw. 2020 07; 18(7):793. Tempero M. PMID: 32634769.
      View in: PubMed   Mentions:    Fields:    
    19. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clin Cancer Res. 2020 09 15; 26(18):4743-4747. Hafez N, Rugo HS, Tempero MA, Fox E, Reaman GH, Lyerly HK, Walker D, LoRusso PM. PMID: 32571790.
      View in: PubMed   Mentions:    Fields:    
    20. My Two-Dimensional Life. J Natl Compr Canc Netw. 2020 06; 18(6):649. Tempero M. PMID: 32502979.
      View in: PubMed   Mentions:    Fields:    
    21. Lessons From a Tiny Strand of RNA. J Natl Compr Canc Netw. 2020 05; 18(5):493. Tempero M. PMID: 32380459.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clin Cancer Res. 2020 07 15; 26(14):3578-3588. Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. PMID: 32273276.
      View in: PubMed   Mentions: 12     Fields:    
    23. Health and the Gut Microbiome: Who Knew? J Natl Compr Canc Netw. 2020 04; 18(4):365. Tempero M. PMID: 32259784.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review. Pancreas. 2020 03; 49(3):393-407. Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY. PMID: 32132518.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Taking Our Hands Off the Wheel. J Natl Compr Canc Netw. 2020 03; 18(3):221. Tempero M. PMID: 32135519.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. It's About Time! J Natl Compr Canc Netw. 2020 02; 18(2):115. Tempero M. PMID: 32023523.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. This Time I Mean It! J Natl Compr Canc Netw. 2020 01; 18(1):1. Tempero M. PMID: 31910382.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Santa, Can You Hear Me? J Natl Compr Canc Netw. 2019 12; 17(12):1455. Tempero M. PMID: 31805531.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. PMID: 31634155.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Giving Thanks. J Natl Compr Canc Netw. 2019 11 01; 17(11):1267. Tempero M. PMID: 31693979.
      View in: PubMed   Mentions:    Fields:    
    31. My Summer Vacation. J Natl Compr Canc Netw. 2019 10 01; 17(10):1147. Tempero M. PMID: 31590150.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. We All Own This! J Natl Compr Canc Netw. 2019 09 01; 17(9):1021. Tempero M. PMID: 31487675.
      View in: PubMed   Mentions:    Fields:    
    33. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 02 10; 38(5):496-520. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. PMID: 31381464.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    34. Managing Expectations. J Natl Compr Canc Netw. 2019 08 01; 17(8):893. Tempero M. PMID: 31390589.
      View in: PubMed   Mentions:    Fields:    
    35. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas. 2019 08; 48(7):927-930. Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. PMID: 31268983.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Taking the Mountain to Muhammad. J Natl Compr Canc Netw. 2019 07 01; 17(7):767. Tempero M. PMID: 31319392.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Tackling Cost: A Prescription for Spending Wisely. J Natl Compr Canc Netw. 2019 06 01; 17(6):633. Tempero M. PMID: 31200360.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw. 2019 05 01; 17(5.5):603-605. Tempero MA. PMID: 31117041.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    39. Finding Room for Success. J Natl Compr Canc Netw. 2019 05 01; 17(5):407. Tempero M. PMID: 31085761.
      View in: PubMed   Mentions:    Fields:    
    40. The Time Has Come! J Natl Compr Canc Netw. 2019 04 01; 17(4):295. Tempero M. PMID: 30959464.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 04; 18(2):241-251. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. PMID: 30267352.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    42. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019 03; 43(3):334-340. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. PMID: 30211728.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 03 01; 17(3):202-210. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. PMID: 30865919.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    44. Kids, There's an App for That! J Natl Compr Canc Netw. 2019 02; 17(2):101. Tempero M. PMID: 30787121.
      View in: PubMed   Mentions:    Fields:    
    45. New Year, New Look! J Natl Compr Canc Netw. 2019 01; 17(1):1. Tempero M. PMID: 30659122.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. An Oncologist's Letter to Santa: Bring Me Drugs! J Natl Compr Canc Netw. 2018 12; 16(12):1411. Tempero M. PMID: 30545986.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. I'm Conflicted. Are You? J Natl Compr Canc Netw. 2018 11; 16(11):1273. Tempero M. PMID: 30442729.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. One Size Fits All? Really? J Natl Compr Canc Netw. 2018 10; 16(10):1161. Tempero M. PMID: 30323084.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    49. Getting What You Pay For: Finding Value in Cancer Care. J Natl Compr Canc Netw. 2018 09; 16(9):1031. Tempero M. PMID: 30181413.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Notes From the Other Side. J Natl Compr Canc Netw. 2018 08; 16(8):921-922. Tempero M. PMID: 30099366.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. PMID: 30063366.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    52. Genomic Medicine Takes the Stage, Again! J Natl Compr Canc Netw. 2018 07; 16(7):795. Tempero M. PMID: 30006420.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Movin' On Up! J Natl Compr Canc Netw. 2018 06; 16(6):675. Tempero M. PMID: 29891517.
      View in: PubMed   Mentions:    Fields:    
    54. Getting Into the Weeds. J Natl Compr Canc Netw. 2018 05; 16(5):457. Tempero M. PMID: 29752317.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    55. Standing Together or Alone. J Natl Compr Canc Netw. 2018 Apr; 16(4):341. Tempero M. PMID: 29632051.
      View in: PubMed   Mentions:    Fields:    
    56. Molecular Diagnostics: Another Battle Brewing. J Natl Compr Canc Netw. 2018 Mar; 16(3):225. Tempero M. PMID: 29523658.
      View in: PubMed   Mentions:    Fields:    
    57. Extending Our Reach-Will Telemedicine Get Us There? J Natl Compr Canc Netw. 2018 Feb; 16(2):107. Tempero M. PMID: 29439170.
      View in: PubMed   Mentions:    Fields:    
    58. Revisiting New Year's Resolutions. J Natl Compr Canc Netw. 2018 01; 16(1):1. Tempero M. PMID: 29295874.
      View in: PubMed   Mentions:    Fields:    
    59. It's About Time! J Natl Compr Canc Netw. 2017 12; 15(12):1443. Tempero M. PMID: 29223979.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    60. Who's Watching the Kids? J Natl Compr Canc Netw. 2017 11; 15(11):1289. Tempero M. PMID: 29118220.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Introduction: Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. Cancer J. 2017 Nov/Dec; 23(6):309. Tempero MA. PMID: 29189324.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    62. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. PMID: 29228650.
      View in: PubMed   Mentions: 7     Fields:    
    63. HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018 Jan; 14(1):13-22. Doherty GJ, Tempero M, Corrie PG. PMID: 29235360.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    64. Serving "a la CAR-T": Value-Based Pricing and Gene Therapy. J Natl Compr Canc Netw. 2017 10; 15(10):1179. Tempero M. PMID: 28982741.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    65. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 12; 22(12):1427-e129. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. PMID: 28935773.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    66. Your Genes: Getting the Best Fit. J Natl Compr Canc Netw. 2017 09; 15(9):1083. Tempero M. PMID: 28874592.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    67. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 08; 15(8):1028-1061. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. PMID: 28784865.
      View in: PubMed   Mentions: 185     Fields:    Translation:Humans
    68. When It's Really Good, We Know It! J Natl Compr Canc Netw. 2017 08; 15(8):973. Tempero M. PMID: 28784856.
      View in: PubMed   Mentions:    Fields:    
    69. Reducing the Cost of Cancer Care: When Less Is More. J Natl Compr Canc Netw. 2017 07; 15(7):853. Tempero M. PMID: 28687571.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Getting Practical About Recertification. J Natl Compr Canc Netw. 2017 06; 15(6):753. Tempero M. PMID: 28596253.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Hospice: Angels at Work. J Natl Compr Canc Netw. 2017 05; 15(5):549. Tempero M. PMID: 28476733.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. Active Systemic Treatment of Pancreatic Cancer. J Natl Compr Canc Netw. 2017 05; 15(5S):723-725. Tempero M. PMID: 28515255.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Politics as Usual-Not! J Natl Compr Canc Netw. 2017 04; 15(4):425. Tempero M. PMID: 28404753.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. J Natl Cancer Inst. 2017 04 01; 109(4). Capello M, Bantis LE, Scelo G, Zhao Y, Li P, Dhillon DS, Patel NJ, Kundnani DL, Wang H, Abbruzzese JL, Maitra A, Tempero MA, Brand R, Firpo MA, Mulvihill SJ, Katz MH, Brennan P, Feng Z, Taguchi A, Hanash SM. PMID: 28376157.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    75. Saying Yes. J Natl Compr Canc Netw. 2017 03; 15(3):277. Tempero M. PMID: 28275029.
      View in: PubMed   Mentions:    Fields:    
    76. Mad About MACRA. J Natl Compr Canc Netw. 2017 02; 15(2):137. Tempero M. PMID: 28188184.
      View in: PubMed   Mentions:    Fields:    
    77. New Year's Resolutions. J Natl Compr Canc Netw. 2017 01; 15(1):1. Tempero M. PMID: 28040714.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Assessing Researcher Needs for a Virtual Biobank. Biopreserv Biobank. 2017 Jun; 15(3):203-210. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. PMID: 27929677.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    79. An Oncologist's Letter to Santa. J Natl Compr Canc Netw. 2016 12; 14(12):1491. Tempero M. PMID: 27956532.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Hypermutation In Pancreatic Cancer. Gastroenterology. 2017 01; 152(1):68-74.e2. Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative , Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV. PMID: 27856273.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    81. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 11; 45(10):1394-1400. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. PMID: 27171514.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    82. My Knee Hurts! J Natl Compr Canc Netw. 2016 11; 14(11):1335. Tempero M. PMID: 27799504.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    83. Crossing the Line. J Natl Compr Canc Netw. 2016 10; 14(10):1191. Tempero M. PMID: 27697973.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. Hillary and Donald, Our Patients Are Watching. J Natl Compr Canc Netw. 2016 09; 14(9):1047. Tempero M. PMID: 27587617.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    85. I'll Have Another Shot, Please! J Natl Compr Canc Netw. 2016 08; 14(8):929. Tempero M. PMID: 27496107.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    86. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. PMID: 27444658.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    87. The Greatest Show on Earth! J Natl Compr Canc Netw. 2016 07; 14(7):813. Tempero M. PMID: 27407120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    88. Did the IRB Approve This? J Natl Compr Canc Netw. 2016 06; 14(6):699. Tempero M. PMID: 27283161.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    89. Closely Guarded Secrets. J Natl Compr Canc Netw. 2016 05; 14(5):487. Tempero M. PMID: 27160226.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Pancreatic cancer. Nat Rev Dis Primers. 2016 04 21; 2:16022. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. PMID: 27158978.
      View in: PubMed   Mentions: 334     Fields:    Translation:HumansAnimals
    91. Letting Nature Loose. J Natl Compr Canc Netw. 2016 Apr; 14(4):367. Tempero M. PMID: 27059185.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. PMID: 26390428.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCellsCTClinical Trials
    93. Promising the Moon! J Natl Compr Canc Netw. 2016 Mar; 14(3):237. Tempero M. PMID: 26957609.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    94. Put Us Out of Business--Please! J Natl Compr Canc Netw. 2016 Feb; 14(2):123. Tempero M. PMID: 26850482.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    95. Pancreatic Adenocarcinoma: The Emperor of All Cancer Maladies. J Oncol Pract. 2016 Jan; 12(1):29-30. Tempero M. PMID: 26759462.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    96. Bringing Biosimilars to the Clinic: What's the Fuss? J Natl Compr Canc Netw. 2016 Jan; 14(1):1. Tempero M. PMID: 26733549.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 2016 Mar; 6(3):270-85. Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM. PMID: 26715645.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansAnimalsCells
    98. Paying Less for High-Value Care--Are You Kidding Me? J Natl Compr Canc Netw. 2015 Dec; 13(12):1453. Tempero M. PMID: 26656513.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. At Last: Getting Paid to Think! J Natl Compr Canc Netw. 2015 Nov; 13(11):1297. Tempero M. PMID: 26553759.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    100. Putting an End to It! J Natl Compr Canc Netw. 2015 Oct; 13(10):1167. Tempero M. PMID: 26483055.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Crossing Over. J Natl Compr Canc Netw. 2015 Sep; 13(9):1053. Tempero M. PMID: 26358787.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    102. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    103. Move It! J Natl Compr Canc Netw. 2015 Aug; 13(8):939. Tempero M. PMID: 26285237.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Express Scripts? Really? J Natl Compr Canc Netw. 2015 Jul; 13(7):827. Tempero M. PMID: 26150575.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    105. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    106. Improving Access to Drugs--Big Pharma Comes to the Table. J Natl Compr Canc Netw. 2015 Jun; 13(6):703. Tempero M. PMID: 26085384.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Multidisciplinary management of pancreatic cancer. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):700-2. Tempero MA. PMID: 25995435.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    108. Reducing costs by changing behavior-really? J Natl Compr Canc Netw. 2015 May; 13(5):499. Tempero M. PMID: 25964633.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    109. Turf war over diagnostic testing. J Natl Compr Canc Netw. 2015 Apr; 13(4):375. Tempero M. PMID: 25870372.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    110. Putting precision medicine on the national agenda. J Natl Compr Canc Netw. 2015 Mar; 13(3):251. Tempero M. PMID: 25736000.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26; 518(7540):495-501. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Australian Pancreatic Cancer Genome Initiative , Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM. PMID: 25719666.
      View in: PubMed   Mentions: 781     Fields:    Translation:HumansAnimalsCells
    112. All bundled up! J Natl Compr Canc Netw. 2015 Feb; 13(2):121. Tempero M. PMID: 25691601.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    113. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A, American Society of Clinical Oncology . PMID: 25605844.
      View in: PubMed   Mentions: 189     Fields:    Translation:Humans
    114. Meet the New JNCCN! J Natl Compr Canc Netw. 2015 Jan; 13(1):1. Tempero M. PMID: 25583762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    115. Happy anniversary! J Natl Compr Canc Netw. 2014 Dec; 12(12):1653. Tempero M. PMID: 25505204.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    116. Bringing science to clinical practice. J Natl Compr Canc Netw. 2014 Nov; 12(11):1495. Tempero M. PMID: 25361794.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    117. Cancer screening: when is the juice worth the squeeze? J Natl Compr Canc Netw. 2014 Oct; 12(10):1359. Tempero M. PMID: 25313175.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. PMID: 25199993.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    119. Getting what you pay for: finding value in cancer care. J Natl Compr Canc Netw. 2014 Sep; 12(9):1199. Tempero M. PMID: 25190688.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    120. Incentive-based oncology: unintended consequences? J Natl Compr Canc Netw. 2014 Aug; 12(8):1069. Tempero M. PMID: 25099438.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    121. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. PMID: 25099441.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    122. A publicly funded clinical trials network: do we need it? J Natl Compr Canc Netw. 2014 Jul; 12(7):953. Tempero M. PMID: 24994914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    123. Embracing team-based oncology care. J Natl Compr Canc Netw. 2014 Jun; 12(6):845. Tempero M. PMID: 24925194.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    124. Managing the fruits of our success. J Natl Compr Canc Netw. 2014 May; 12(5):603. Tempero M. PMID: 24812128.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    125. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. PMID: 24622062.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    126. The changing face of community practice: the new normal. J Natl Compr Canc Netw. 2014 Apr; 12(4):449. Tempero M. PMID: 24717562.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    127. JNCCN going forward. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):301. Tempero M. PMID: 24616533.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    128. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    129. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. PMID: 23880820.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    130. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013 Jun; 144(6):1316-26. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. PMID: 23622141.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    131. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Prestrud AA, Falanga A, American Society of Clinical Oncology Clinical Practice . PMID: 23669224.
      View in: PubMed   Mentions: 201     Fields:    Translation:Humans
    132. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res. 2013 Feb 01; 19(3):538-40. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM. PMID: 23344262.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    133. Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J. 2012 Nov-Dec; 18(6):653-64. Cinar P, Tempero MA. PMID: 23187854.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    134. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Nov 15; 491(7424):399-405. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Australian Pancreatic Cancer Genome Initiative , Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. PMID: 23103869.
      View in: PubMed   Mentions: 755     Fields:    Translation:HumansAnimalsCells
    135. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    136. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. PMID: 23053263.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    137. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA, National Comprehensive Cancer Networks . PMID: 22679115.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    138. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. PMID: 21460848.
      View in: PubMed   Mentions: 515     Fields:    Translation:HumansAnimalsCells
    139. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jul; 22(7):1500-1506. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E. PMID: 21199884.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    140. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res. 2011 Jan 15; 17(2):203-5. Collisson E, Tempero M. PMID: 21106729.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    141. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2010 Sep; 8(9):972-1017. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma . PMID: 20876541.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    142. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8. International Cancer Genome Consortium , Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cros A, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BB, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbauer H, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, et al. PMID: 20393554.
      View in: PubMed   Mentions: 863     Fields:    Translation:HumansCells
    143. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    144. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol. 2009 Nov 20; 27(33):5660-9. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J. PMID: 19858397.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansAnimals
    145. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. PMID: 19858396.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    146. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. Ko AH, Tempero MA. PMID: 19041649.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    147. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. PMID: 18815548.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    148. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. PMID: 18379729.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    149. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 18181045.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    150. How I treat pancreatic ductal adenocarcinoma. J Oncol Pract. 2008 Jan; 4(1):46-7. Tempero MA. PMID: 20859443.
      View in: PubMed   Mentions:    Fields:    
    151. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2007 Nov; 5(10):998-1033. Tempero M, Arnoletti JP, Ben-Josef E, Bhargava P, Casper ES, Kim P, Malafa MP, Nakakura EK, Shibata S, Talamonti M, Wang H, Willett C. PMID: 18053426.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    152. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol. 2007 Jun; 18 Suppl 7:vii1-vii10. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PG, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J. PMID: 17600091.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    153. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. PMID: 17363191.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    154. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A, Workshop Program Committee . PMID: 17655039.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    155. Phase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2007 Feb; 25(1):85-94. Jhawer M, Rosen L, Dancey J, Hochster H, Hamburg S, Tempero M, Clendeninn N, Mani S. PMID: 16957834.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    156. Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res. 2006 Jan 01; 66(1):14-7. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, Tuveson DA. PMID: 16397208.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    157. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 16344320.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    158. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. Ko AH, Tempero MA. PMID: 16183478.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    159. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2005 Sep; 3(5):598-626. Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA, National Comprehensive Cancer Network . PMID: 16194453.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    160. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. Ko AH, Tempero MA. PMID: 16194454.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    161. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. PMID: 15999098.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    162. Clinical oncology 2004: the president's report. J Clin Oncol. 2004 Nov 15; 22(22):4437-41. Tempero MA. PMID: 15542796.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    163. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003 Sep 15; 21(18):3402-8. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. PMID: 12885837.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCTClinical Trials
    164. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. PMID: 15361643.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    165. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant. 2002 Sep; 2(8):774-9. Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, McCashland T, Sorrell M, Tempero M, Langnas A. PMID: 12243499.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    166. Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med. 2002 Jul; 43(7):957-67. Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J. PMID: 12097469.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    167. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. Ko AH, Tempero MA. PMID: 11937010.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    168. Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice. J Am Pharm Assoc (Wash). 2002 Jan-Feb; 42(1):93-100. Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA. PMID: 11833524.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    169. A white paper: the product of a pancreas cancer think tank. Cancer Res. 2001 Jun 15; 61(12):4923-32. Kern S, Hruban R, Hollingsworth MA, Brand R, Adrian TE, Jaffee E, Tempero MA. PMID: 11406572.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    170. Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members. J Nucl Med. 2001 Jun; 42(6):907-15. Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, Dukat VJ, Hohenstein MA, Gobar LS, Vose JM. PMID: 11390555.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    171. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999 Dec; 117(6):1464-84. DiMagno EP, Reber HA, Tempero MA. PMID: 10579989.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    172. Pancreatic cancer. Curr Opin Oncol. 1998 Jul; 10(4):362-6. Brand RE, Tempero MA. PMID: 9702405.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    173. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 1998 May 01; 82(9):1800-1. Tempero MA, Brand R. PMID: 9576306.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    174. Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy. J Vasc Interv Radiol. 1998 Mar-Apr; 9(2):233-9. Habbe TG, McCowan TC, Goertzen TC, Leveen RF, Culp WC, Tempero MA. PMID: 9540905.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    175. Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med. 1997 Apr; 38(4):512-6. Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA. PMID: 9098192.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    176. Walking a difficult path is easier with a friend. Thoughts from a practicing oncologist. Ann N Y Acad Sci. 1997 Feb 20; 809:237-42. Tempero MA. PMID: 9103574.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    177. Radiolabeled iododeoxyuridine: safety evaluation. J Nucl Med. 1996 Apr; 37(4 Suppl):13S-16S. Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK. PMID: 8676196.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    178. Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):156-65. Sivinski CL, Lindner DJ, Borden EC, Tempero MA. PMID: 8770771.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    179. Comparison of subcutaneous and intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor for peripheral blood stem cell mobilization. J Hematother. 1995 Apr; 4(2):81-4. Kessinger A, Bishop MR, Anderson JR, Armitage JO, Bierman PJ, Reed EC, Tarantolo S, Tempero MA, Vose JM, Warkentin PI. PMID: 7543352.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    180. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev. 1994 Mar; 3(2):155-60. Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. PMID: 8049637.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    181. Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A. Int J Pancreatol. 1994 Feb; 15(1):43-50. Haga Y, Sivinski CL, Woo D, Tempero MA. PMID: 8195641.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    182. Purification and analysis of glycoproteins bearing blood group-A determinants from hamster pancreatic ductal adenocarcinomas. Carcinogenesis. 1992 Oct; 13(10):1829-33. Hirota M, Pour PM, Tempero MA, Chaney WG. PMID: 1385001.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    183. Quantitation of metastatic tumor burden from human colon tumor xenografts using radiolabelled monoclonal antibody 17-A fragments. Tumour Biol. 1992; 13(4):195-206. Joshi SS, Mann SL, Tempero MA, Crouse DA, Stratbucker RA, Quaife MA, Sharp JG. PMID: 1411138.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    184. Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma. Int J Pancreatol. 1991; 9:125-34. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. PMID: 1744438.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    185. Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol. 1990 Dec; 8(12):2019-26. Tempero MA, Sivinski C, Steplewski Z, Harvey E, Klassen L, Kay HD. PMID: 2121912.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    186. Advances in the medical management of advanced gastrointestinal cancers. Curr Opin Oncol. 1990 Aug; 2(4):747-53. Tempero MA. PMID: 2095882.
      View in: PubMed   Mentions:    Fields:    
    187. Chemoprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res. 1989 Nov 01; 49(21):5793-7. Tempero MA, Nishioka K, Knott K, Zetterman RK. PMID: 2507137.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    188. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Hum Pathol. 1989 Sep; 20(9):832-8. Takiyama Y, Tempero MA, Takasaki H, Onda M, Tsuchiya R, Büchler M, Ness M, Colcher D, Schlom J, Pour PM. PMID: 2673979.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    189. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. Int J Cancer. 1988 Nov 15; 42(5):681-6. Takasaki H, Tempero MA, Uchida E, Büchler M, Ness MJ, Burnett DA, Metzgar RS, Colcher D, Schlom J, Pour PM. PMID: 3053465.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    190. Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res. 1988 Oct 01; 48(19):5422-6. Pour PM, Tempero MM, Takasaki H, Uchida E, Takiyama Y, Burnett DA, Steplewski Z. PMID: 3166398.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    191. Immunohistochemistry with monoclonal antibody B72.3 as an adjunct in the cytologic diagnosis of pancreatic carcinoma. Mod Pathol. 1988 Jul; 1(4):279-83. Ness MJ, Pour PM, Tempero MA, Linder J. PMID: 2467286.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    192. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res. 1988 Mar 15; 48(6):1435-8. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. PMID: 3162196.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    193. Effects of sodium cholate on experimental carcinogenesis and cell proliferation in an excluded colonic segment. J Surg Oncol. 1987 Dec; 36(4):253-8. Tempero MA, Zetterman RK. PMID: 3695530.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    194. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987 Oct 15; 47(20):5501-3. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. PMID: 3308077.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    195. Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissue. Int J Pancreatol. 1987 Oct-Dec; 2(5-6):349-60. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. PMID: 3320227.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    196. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl. 1987; 1:145-8. Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. PMID: 3319143.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    197. In vitro regulation of human lymphocyte proliferation by selenium. Biol Trace Elem Res. 1986 Dec; 11(1):129-46. Petrie HT, Klassen LW, Tempero MA, Kay HD. PMID: 24254509.
      View in: PubMed   Mentions: 1     Fields:    
    198. Monoclonal antibody CO17-1A and leukapheresis in immunotherapy of pancreatic cancer. Hybridoma. 1986 Jul; 5 Suppl 1:S133-8. Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. PMID: 3744378.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    199. Bile acids, ornithine decarboxylase, and cell proliferation in colon cancer: a review. Dig Dis. 1986; 4(1):49-56. Tempero M. PMID: 3545561.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    Margaret's Networks
    Concepts (507)
    Derived automatically from this person's publications.
    _
    Co-Authors (56)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _